Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein

Chih Hsin Yang, Ching Ju Huang, Chao Shun Yang, Yu Chuan Chu, Ann Lii Cheng, Jacqueline Whang-Peng, Pan Chyr Yang

研究成果: 雜誌貢獻文章同行評審

92 引文 斯高帕斯(Scopus)

摘要

Gefitinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. It is conceivable that gefitinib may inhibit functions of ATP-binding cassette (ABC) transporters by binding at their ATP-binding sites. The aim of this study is to systematically explore the combined effect of gefitinib and chemotherapeutic agents in gefitinib- insensitive multidrug resistant (MDR) cells that overexpress ABC transporters. MCF7 breast carcinoma cells and CLI lung adenocarcinoma cells were both insensitive to gefitinib. MDR cancer cells were developed by stepwise escalating concentrations of each chemotherapeutic agent in culture media. Cells that overexpress P-glycoprotein (MCF7/Adr and CLI/Pac), breast cancer-resistant protein (MCF7/TPT and CLI/Tpt), and MDR-associated protein 1 (MCF7/Vp) were used in this study. All resistant mutants were insensitive to gefitinib. Gefitinib (0.3-3 μmol/L) added to culture media had no effect on IC50 values of paclitaxel, topotecan, doxorubicin, or etoposide in wild-type MCF7 or CLI cells. In contrast, these concentrations of gefitinib caused a dose-dependent reversal of resistance to paclitaxel in CLI/Pac cells, to doxorubicin in MCF7/ADR cells, and to topotecan in CLI/Tpt and MCF7/TPT cells. Gefitinib had no influence on sensitivity to etoposide in MDR-associated protein1 overexpressing MCF7/VP cells. Topotecan efflux was inhibited and accumulation was partially restored in CLI/Tpt and MCF7/TPT cells when cells were incubated simultaneously with gefitinib. Our results suggest that the interaction of gefitinib and chemotherapeutic agents does occur in cells expressing one of these two proteins.
原文英語
頁(從 - 到)6943-6949
頁數7
期刊Cancer Research
65
發行號15
DOIs
出版狀態已發佈 - 8月 1 2005
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein」主題。共同形成了獨特的指紋。

引用此